103 related articles for article (PubMed ID: 17998283)
1. DeltaNp63 expression is associated with poor survival in ovarian cancer.
Marchini S; Marabese M; Marrazzo E; Mariani P; Cattaneo D; Fossati R; Compagnoni A; Fruscio R; Lissoni AA; Broggini M
Ann Oncol; 2008 Mar; 19(3):501-7. PubMed ID: 17998283
[TBL] [Abstract][Full Text] [Related]
2. Frequent alteration of p63 expression in human primary bladder carcinomas.
Park BJ; Lee SJ; Kim JI; Lee SJ; Lee CH; Chang SG; Park JH; Chi SG
Cancer Res; 2000 Jul; 60(13):3370-4. PubMed ID: 10910040
[TBL] [Abstract][Full Text] [Related]
3. p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.
Coates PJ; Nenutil R; Holcakova J; Nekulova M; Podhorec J; Svoboda M; Vojtesek B
Virchows Arch; 2018 Mar; 472(3):351-359. PubMed ID: 29484502
[TBL] [Abstract][Full Text] [Related]
4. ΔNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis.
Park S; Lee S; Kim J; Kim G; Park KH; Kim TU; Chung D; Lee H
PLoS One; 2019; 14(4):e0214867. PubMed ID: 30973901
[TBL] [Abstract][Full Text] [Related]
5. Expression of p63 (TA and deltaN isoforms) in human primary well differentiated buccal carcinomas.
Chen YK; Hsue SS; Lin LM
Int J Oral Maxillofac Surg; 2004 Jul; 33(5):493-7. PubMed ID: 15183414
[TBL] [Abstract][Full Text] [Related]
6. Overexpression and ratio disruption of ΔNp63 and TAp63 isoform equilibrium in endometrial adenocarcinoma: correlation with obesity, menopause, and grade I/II tumors.
Vakonaki E; Soulitzis N; Sifakis S; Papadogianni D; Koutroulakis D; Spandidos DA
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1271-8. PubMed ID: 22441934
[TBL] [Abstract][Full Text] [Related]
7. Regulation of limbal keratinocyte proliferation and differentiation by TAp63 and DeltaNp63 transcription factors.
Wang DY; Cheng CC; Kao MH; Hsueh YJ; Ma DH; Chen JK
Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3102-8. PubMed ID: 16123408
[TBL] [Abstract][Full Text] [Related]
8. A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer.
Iwata T; Uramoto H; Sugio K; Fujino Y; Oyama T; Nakata S; Ono K; Morita M; Yasumoto K
Lung Cancer; 2005 Oct; 50(1):67-73. PubMed ID: 15950316
[TBL] [Abstract][Full Text] [Related]
9. Expression of the p53 family in lung cancer.
Uramoto H; Sugio K; Oyama T; Nakata S; Ono K; Nozoe T; Yasumoto K
Anticancer Res; 2006; 26(3A):1785-90. PubMed ID: 16827107
[TBL] [Abstract][Full Text] [Related]
10. Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes.
Abbas HA; Bui NHB; Rajapakshe K; Wong J; Gunaratne P; Tsai KY; Coarfa C; Flores ER
Cancer Res; 2018 Jan; 78(2):451-462. PubMed ID: 29180475
[TBL] [Abstract][Full Text] [Related]
11. ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity.
Uchida K; Ross H; Lotan T; Pignon JC; Signoretti S; Epstein JI; Illei PB
Hum Pathol; 2015 Mar; 46(3):384-9. PubMed ID: 25548110
[TBL] [Abstract][Full Text] [Related]
12. TAp63 and ΔNp63 (p40) in prostate adenocarcinomas: ΔNp63 associates with a basal-like cancer stem cell population but not with metastasis.
Galoczova M; Nenutil R; Pokorna Z; Vojtesek B; Coates PJ
Virchows Arch; 2021 Apr; 478(4):627-636. PubMed ID: 33037932
[TBL] [Abstract][Full Text] [Related]
13. Expression of deltaNp63 in squamous cell carcinoma of the esophagus.
Morita M; Uramoto H; Nakata S; Ono K; Sugaya M; Yoshimatsu T; Oyama T; Hanagiri T; Sugio K; Yasumoto K
Anticancer Res; 2005; 25(5):3533-9. PubMed ID: 16101176
[TBL] [Abstract][Full Text] [Related]
14. DNA-binding and transactivation activities are essential for TAp63 protein degradation.
Ying H; Chang DL; Zheng H; McKeon F; Xiao ZX
Mol Cell Biol; 2005 Jul; 25(14):6154-64. PubMed ID: 15988026
[TBL] [Abstract][Full Text] [Related]
15. The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells.
Petitjean A; Cavard C; Shi H; Tribollet V; Hainaut P; Caron de Fromentel C
Oncogene; 2005 Jan; 24(3):512-9. PubMed ID: 15543231
[TBL] [Abstract][Full Text] [Related]
16. ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression.
Papadimitriou MA; Avgeris M; Levis PK; Tokas T; Stravodimos K; Scorilas A
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3075-3087. PubMed ID: 31595333
[TBL] [Abstract][Full Text] [Related]
17. ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer.
Gaya JM; López-Martínez JM; Karni-Schmidt O; Bonal DM; Algaba F; Palou J; Villavicencio H; Benson MC; Cordon-Cardo C; Castillo-Martin M
J Urol; 2015 Apr; 193(4):1144-50. PubMed ID: 25444981
[TBL] [Abstract][Full Text] [Related]
18. p63 expression in epithelial ovarian tumors.
Poli Neto OB; Candido Dos Reis FJ; Zambelli Ramalho LN; Nogueira AA; de Andrade JM
Int J Gynecol Cancer; 2006; 16(1):152-5. PubMed ID: 16445626
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of p63 isoforms in normal tissues and neoplastic cells.
Nylander K; Vojtesek B; Nenutil R; Lindgren B; Roos G; Zhanxiang W; Sjöström B; Dahlqvist A; Coates PJ
J Pathol; 2002 Dec; 198(4):417-27. PubMed ID: 12434410
[TBL] [Abstract][Full Text] [Related]
20. p63 protein expression in high risk diffuse large B-cell lymphoma.
Hallack Neto AE; Siqueira SA; Dulley FL; Ruiz MA; Chamone DA; Pereira J
J Clin Pathol; 2009 Jan; 62(1):77-9. PubMed ID: 19103865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
